Genetic polymorphisms and its influence in chemotherapeutic treatment of leukemic patients

Authors

  • Luis Quiñones Sepúlveda Bioquímico. Centro de Investigaciones Farmacológicas y Toxicológicas, Programa de Farmacología Molecular y Clínica, ICBM, Facultad de Medicina, División Occidente, Universidad de Chile. Santiago
  • Angela Roco Arriagada Bioquímico. Centro de Investigaciones Farmacológicas y Toxicológicas, Programa de Farmacología Molecular y Clínica, ICBM, Facultad de Medicina, División Occidente, Universidad de Chile. Santiago
  • Valentina Squicciarini Rueda Bioquímico. Centro de Investigaciones Farmacológicas y Toxicológicas, Programa de Farmacología Molecular y Clínica, ICBM, Facultad de Medicina, División Occidente, Universidad de Chile. Santiago
  • Dante D. Cáceres Lillo Médico Veterinario. División de Epidemiología, Escuela de Salud Pública, Facultad de Medicina Universidad de Chile. Santiago
  • Carla Miranda Melo Bioquímico. Centro de Investigaciones Farmacológicas y Toxicológicas, Programa de Farmacología Molecular y Clínica, ICBM, Facultad de Medicina, División Occidente, Universidad de Chile. Santiago
  • Jaime Sasso Aguirre 6 Químico – Farmacéutico. Centro de Investigaciones Farmacológicas y Toxicológicas, Programa de Farmacología Molecular y Clínica, ICBM, Facultad de Medicina, División Occidente, Universidad de Chile. Santiago
  • José A.G Agúndez Facultad de Medicina, Universidad de Extremadura
  • Elena García-Martin Facultad de Medicina, Universidad de Extremadura
  • Iván Saavedra Saavedra Químico – Farmacéutico. Centro de Investigaciones Farmacológicas y Toxicológicas, Programa de Farmacología Molecular y Clínica, ICBM, Facultad de Medicina, División Occidente, Universidad de Chile. Santiago

Keywords:

Pharmacogenetics, leukemia, biotransformation, chemotherapy

Abstract

In Chile, the incidence of leukemia is 4.2/100.000 adults a year. Among them, 2.8/100.000 is acute leukemia and 1.4/100.000 chronic leukemia. The chemotherapy for cancer has been improved through the years in clinical practice and it constitutes a very useful therapeutic option in leukemia. However, its use is limited due to uncertain response; therefore, the pharmacotherapy choice is mainly empiric. In this sense the inter-individual differences in response to antineoplastic drugs could be due to pharmacokinetic factors (affecting absorption, distribution, metabolism and excretion) or pharmacodinamics (affecting receptors or another pharmacological target). It is estimated that genetics accounts for 20 to 95% of variability in therapeutics and toxicological response to drugs, which are mainly metabolized through polymorphic biotransformation enzymes (80%). Therefore, the present review gives a comprehensive study of the probable response of patients to established leukemia chemotherapy treatment in Chile according their genetic profiles on involved metabolizing enzymes.

Downloads

Download data is not yet available.

Published

2010-12-28

How to Cite

Quiñones Sepúlveda, L., Roco Arriagada, A. ., Squicciarini Rueda, V. ., Cáceres Lillo, D. D. ., Miranda Melo, C. ., Sasso Aguirre, J. ., Agúndez, J. A. ., García-Martin, E. ., & Saavedra Saavedra, I. (2010). Genetic polymorphisms and its influence in chemotherapeutic treatment of leukemic patients. Cuadernos Médico Sociales, 50(4), 288–295. Retrieved from https://cuadernosms.cl/index.php/cms/article/view/562

Issue

Section

Artículos originales